Allogene restructures JV; ownership diluted to 15.4%, license royalty amended to flat mid-single-digit

Allogene Therapeutics, Inc.

JV acquires Overland US (lead asset OL-101, autologous GPRC5D-BCMA CAR-T for multiple myeloma).
Overland's ownership in JV increases to 69.63%; Allogene's drops to 15.37% after share incentive plan increase.
Exclusive license royalty changed to flat mid single-digit on net sales in territory, no longer subject to reductions.
Allogene gains termination rights for funding default or failure to initiate tech transfer; license auto-terminates if Allogene's ownership <7.5% unless mutual plan agreed.
Overland distributes all JV shares to HH BioPharma Holdings (HBP), which gets 3 of 5 board seats.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.